Enanta Pharmaceuticals (ENTA) Accumulated Depreciation & Amortization (2016 - 2025)
Enanta Pharmaceuticals (ENTA) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $23.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accumulated Depreciation & Amortization fell 4.96% year-over-year to $23.8 million, compared with a TTM value of $23.8 million through Sep 2025, down 4.96%, and an annual FY2025 reading of $23.8 million, down 4.96% over the prior year.
- Accumulated Depreciation & Amortization was $23.8 million for Q3 2025 at Enanta Pharmaceuticals, up from $22.5 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $25.0 million in Q3 2024 and bottomed at $18.9 million in Q3 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $22.7 million, with a median of $23.1 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization rose 20.75% in 2021, then dropped 4.96% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $18.9 million in 2021, then grew by 15.49% to $21.9 million in 2022, then rose by 8.63% to $23.7 million in 2023, then rose by 5.48% to $25.0 million in 2024, then fell by 4.96% to $23.8 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for ENTA at $23.8 million in Q3 2025, $22.5 million in Q2 2025, and $25.0 million in Q3 2024.